Communiqués Acurx Pharmaceuticals, Inc.

Actions

ACXP

US00510M2035

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 01/10/2026			Après clôture 01:20:48
1,260 ^USD	0,00%		1,270	+0,79%

29/09	Acurx Pharmaceuticals, Inc. inclut le premier patient dans l’essai clinique PATHFINDER sur l’ibezapolstat chez des patients atteints d’une infection à C. difficile à récidives multiples	CI
17/08	Acurx Pharmaceuticals reçoit l'accord conditionnel de la FDA et l'homologation de l'USPTO pour la marque CIFBEZY associée à l'ibezapolstat	CI

Communiqués

29/09	Acurx Pharmaceuticals Announces First Patient Enrolled in PATHFINDER Clinical Trial of Ibezapolstat in Multiply-Recurrent C. difficile Infection	PR
14/09	Acurx Announces Presentation of a Scientific Poster at the Premier International C. difficile Symposium (ICDS) Demonstrating Superior In Vitro Kill Kinetics of Ibezapolstat vs. Vancomycin and Fidaxomicin (Standards of Care) in Clostridioides difficile and Vancomycin-Resistant Enterococcus Co-Cultures	PR
17/08	Acurx Pharmaceuticals Receives FDA Conditional Acceptance and USPTO Trademark Allowance for the Company's Brand Name for Ibezapolstat	PR
14/08	Acurx Pharmaceuticals, Inc. Reports Second Quarter 2026 results and provides business update	PR
12/08	Japan and Mexico Patent Offices Both Grant Acurx Pharmaceuticals New Patents for DNA Polymerase IIIC Inhibitor Antibiotics	PR
10/08	Acurx Announces Scientific Partnership with Leiden University Medical Center to Advance Development of Acurx's DNA Polymerase IIIC Inhibitor Antibiotics	PR
03/08	FDA Provides Further Regulatory Guidance to Acurx Pharmaceuticals for the Ibezapolstat Clinical Development Program, Including the Potential for a Single-Phase 3-Trial Registration Plan and a Trial Design to Support Both Treatment and Reduction of Recurrence of C. difficile Infection	PR
14/07	Acurx Pharmaceuticals Announces Scientific Poster Presentation of Ibezapolstat's Microbiome Preservation Data in Multiply-recurrent C. difficile Infection	PR
08/07	Acurx Pharmaceuticals to Discuss Second Quarter 2026 Financial Results on August 14, 2026 Conference Call and Provide Business Update	PR
16/06	Acurx Pharmaceuticals Announces Presentation of Results from Leiden University Medical Center Public-Private Partnership for Its DNA pol IIIC Inhibitors at the Leiden Early Drug Discovery & Development (LED3) Scientific Conference	PR
19/05	Acurx Pharmaceuticals (NASDAQ: ACXP) Highlights FDA's New CDI Guidance That Could Accelerate Approval Path for Ibezapolstat	AQ
12/05	Acurx Pharmaceuticals, Inc. Reports First Quarter 2026 results and Provides Business Update	PR
04/05	Acurx Announces Scientific Poster Presentation of its DNA pol IIIC Inhibitors' Microbiome Evaluation at ESCMID Global 2026	PR
30/04	Acurx Pharmaceuticals : ESCMID Poster Presentation “Preclinical Microbiome Evaluation of novel PolC-inhibitor compounds (Begum, et. al., April 2026)"	PU
29/04	Acurx Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase	PR
27/04	Acurx Pharmaceuticals, Inc. To Present at The Market Movers Investor Summit	NE
20/04	Acurx Pharmaceuticals to Discuss First Quarter 2026 Financial Results on May 12, 2026 Conference Call and Provide Business Update	PR
16/04	Acurx Pharmaceuticals, Inc. Announces Closing of up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
16/04	Acurx Pharmaceuticals, Inc. Announces up to $7.1 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules	PR
07/04	New to The Street Resigns Acurx Pharmaceuticals, Inc. (NASDAQ:ACXP) to Continue Long-Form Interview Series, Outdoor Media Campaigns and Accredited Investor Events	AQ
04/04	New to The Street Announces Episode 741 Airing Tonight on Bloomberg Television at 6:30 PM EST Featuring Canton Networks, Acme Markets, Virtuix Holdings (VTIX), HPB, Jonas & Redman, Acurx Pharmaceuticals (ACXP), and FreeCast (CAST)	AQ
30/03	Korean Patent Office Grants Acurx Pharmaceuticals New Patent for DNA Polymerase IIIC Inhibitors	PR
13/03	Acurx Pharmaceuticals, Inc. Reports Full Year and Fourth Quarter Results and Provides Business Update	PR
09/03	Acurx Announces New Ibezapolstat Clinical Trial Program in Patients with Recurrent CDI That Has the Potential to Shift the Paradigm of Treatment and Prevention of C. difficile Infection	PR
16/02	Acurx Pharmaceuticals to Discuss Full Year and Fourth Quarter 2025 Financial Results on March 13, 2026 Conference Call and Provide Business Update	PR